555 related articles for article (PubMed ID: 28787506)
21. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study.
Gerhardt SG; McDyer JF; Girgis RE; Conte JV; Yang SC; Orens JB
Am J Respir Crit Care Med; 2003 Jul; 168(1):121-5. PubMed ID: 12672648
[TBL] [Abstract][Full Text] [Related]
22. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial.
Ruttens D; Verleden SE; Demeyer H; Van Raemdonck DE; Yserbyt J; Dupont LJ; Vanaudenaerde BM; Vos R; Verleden GM
PLoS One; 2018; 13(4):e0193564. PubMed ID: 29624575
[TBL] [Abstract][Full Text] [Related]
23. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
Bornhäuser M; Kienast J; Trenschel R; Burchert A; Hegenbart U; Stadler M; Baurmann H; Schäfer-Eckart K; Holler E; Kröger N; Schmid C; Einsele H; Kiehl MG; Hiddemann W; Schwerdtfeger R; Buchholz S; Dreger P; Neubauer A; Berdel WE; Ehninger G; Beelen DW; Schetelig J; Stelljes M
Lancet Oncol; 2012 Oct; 13(10):1035-44. PubMed ID: 22959335
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cell transplantation.
Mo XD; Xu LP; Liu DH; Zhang XH; Chen H; Chen YH; Han W; Wang Y; Wang FR; Wang JZ; Liu KY; Huang XJ
Chin Med J (Engl); 2013 Jul; 126(13):2489-94. PubMed ID: 23823823
[TBL] [Abstract][Full Text] [Related]
25. Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning.
Yoshihara S; Tateishi U; Ando T; Kunitoh H; Suyama H; Onishi Y; Tanosaki R; Mineishi S
Bone Marrow Transplant; 2005 Jun; 35(12):1195-200. PubMed ID: 15852024
[TBL] [Abstract][Full Text] [Related]
26. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
[TBL] [Abstract][Full Text] [Related]
27. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation.
Vos R; Vanaudenaerde BM; Verleden SE; De Vleeschauwer SI; Willems-Widyastuti A; Van Raemdonck DE; Schoonis A; Nawrot TS; Dupont LJ; Verleden GM
Eur Respir J; 2011 Jan; 37(1):164-72. PubMed ID: 20562124
[TBL] [Abstract][Full Text] [Related]
28. Hematopoietic stem cell transplant-related airflow obstruction.
Dudek AZ; Mahaseth H
Curr Opin Oncol; 2006 Mar; 18(2):115-9. PubMed ID: 16462178
[TBL] [Abstract][Full Text] [Related]
29. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation.
Gottlieb J; Szangolies J; Koehnlein T; Golpon H; Simon A; Welte T
Transplantation; 2008 Jan; 85(1):36-41. PubMed ID: 18192909
[TBL] [Abstract][Full Text] [Related]
30. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.
Valery PC; Morris PS; Byrnes CA; Grimwood K; Torzillo PJ; Bauert PA; Masters IB; Diaz A; McCallum GB; Mobberley C; Tjhung I; Hare KM; Ware RS; Chang AB
Lancet Respir Med; 2013 Oct; 1(8):610-620. PubMed ID: 24461664
[TBL] [Abstract][Full Text] [Related]
31. Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome.
Kwok WC; Liang BM; Lui MMS; Tam TCC; Sim JPY; Tse EWC; Leung AYH; Kwong YL; Lie AKW; Ip MSM; Lam DCL
Respirology; 2019 May; 24(5):459-466. PubMed ID: 30663178
[TBL] [Abstract][Full Text] [Related]
32. Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial.
Kor DJ; Carter RE; Park PK; Festic E; Banner-Goodspeed VM; Hinds R; Talmor D; Gajic O; Ware LB; Gong MN;
JAMA; 2016 Jun; 315(22):2406-14. PubMed ID: 27179988
[TBL] [Abstract][Full Text] [Related]
33. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
34. Gastroesophageal reflux disease and its association with bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cell transplant recipients.
Khalid M; Aljurf M; Saleemi S; Khan MQ; Khan B; Ahmed S; Ibrahim Kel T; Mobeireek A; Al Mohareb F; Chaudhri N
Exp Clin Transplant; 2013 Jun; 11(3):270-3. PubMed ID: 23530912
[TBL] [Abstract][Full Text] [Related]
35. Pretransplant serum ferritin level may be a predictive marker for outcomes in patients having undergone allogeneic hematopoietic stem cell transplantation.
Sivgin S; Baldane S; Kaynar L; Kurnaz F; Pala C; Ozturk A; Cetin M; Unal A; Eser B
Neoplasma; 2012; 59(2):183-90. PubMed ID: 22248276
[TBL] [Abstract][Full Text] [Related]
36. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial.
Knoll GA; Humar A; Fergusson D; Johnston O; House AA; Kim SJ; Ramsay T; Chassé M; Pang X; Zaltzman J; Cockfield S; Cantarovich M; Karpinski M; Lebel L; Gill JS
JAMA; 2014 Nov; 312(20):2106-14. PubMed ID: 25399012
[TBL] [Abstract][Full Text] [Related]
37. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.
Uzun S; Djamin RS; Kluytmans JA; Mulder PG; van't Veer NE; Ermens AA; Pelle AJ; Hoogsteden HC; Aerts JG; van der Eerden MM
Lancet Respir Med; 2014 May; 2(5):361-8. PubMed ID: 24746000
[TBL] [Abstract][Full Text] [Related]
38. Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation.
Bergeron A; Chevret S; Chagnon K; Godet C; Bergot E; Peffault de Latour R; Dominique S; de Revel T; Juvin K; Maillard N; Reman O; Contentin N; Robin M; Buzyn A; Socié G; Tazi A
Am J Respir Crit Care Med; 2015 Jun; 191(11):1242-9. PubMed ID: 25835160
[TBL] [Abstract][Full Text] [Related]
39. Preventing and managing bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation.
Chien JW
Expert Rev Respir Med; 2011 Feb; 5(1):127-35. PubMed ID: 21348593
[TBL] [Abstract][Full Text] [Related]
40. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
